secwatch.observer — SEC 8-K summary
======================================

Issuer:     Celcuity Inc. (CELC)
CIK:        0001603454
Form:       8-K
Filed at:   2025-03-31T23:59:59+00:00
Accession:  0001641172-25-001698
Event type: other_material
Sentiment:  negative
Materiality: 0.72
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Celcuity posts Q4 net loss $36.7M, cash $235M, key trial data anticipated in 2025
--------------------------------------------------------------------------------

- Q4 net loss $36.7M ($0.85/share) vs $18.8M ($0.65/share) in Q4 2023; full year net loss $111.8M ($2.83/share).
- Cash, cash equivalents and short-term investments of $235.1M at Dec 31, 2024, expected to fund operations through 2026.
- PIK3CA wild-type cohort of VIKTORIA-1 Phase 3 topline data expected Q2 2025; mutant cohort data in Q4 2025.
- VIKTORIA-2 Phase 3 first patient enrollment on track for Q2 2025; Phase 1b/2 mCRPC data expected late Q2 2025.
- R&D expenses increased to $33.5M in Q4 from $18.1M, driven by ongoing and new clinical trials.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1603454/000164117225001698/0001641172-25-001698-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1603454/000164117225001698/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-001698

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer